Kaori Kawara

Association of UGT2B7 and ABCB1 genotypes with morphine-induced adverse drug reactions in Japanese patients with cancer

Ken‐ichi Fujita, Wataru Yamamoto, Toshimichi Miya et al. · Cancer Chemotherapy and Pharmacology · 2009 · 102 citations

Medicine, Oncology, Pharmacology +8

<i>CYP2A6</i> and the plasma level of 5‐chloro‐2, 4‐dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5‐fluorouracil, respectively, in Japanese patients with cancer given S‐1

Ken‐ichi Fujita, Wataru Yamamoto, Shoji Endo et al. · Cancer Science · 2008 · 62 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Direct Inhibition and Down-regulation by Uremic Plasma Components of Hepatic Uptake Transporter for SN-38, an Active Metabolite of Irinotecan, in Humans

Ken‐ichi Fujita, Tomoko Sugiura, Hidenori Okumura et al. · Pharmaceutical Research · 2013 · 56 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Increased Plasma Concentrations of Unbound SN-38, the Active Metabolite of Irinotecan, in Cancer Patients with Severe Renal Failure

Ken‐ichi Fujita, Yusuke Masuo, Hidenori Okumura et al. · Pharmaceutical Research · 2015 · 38 citations

Medicine, Pharmacokinetics, Pharmacology +17

Association of ATP-Binding Cassette, Sub-family C, Number 2 (ABCC2) Genotype with Pharmacokinetics of Irinotecan in Japanese Patients with Metastatic Colorectal Cancer Treated with Irinotecan Plus Infusional 5-Fluorouracil/Leucovorin (FOLFIRI)

Ken‐ichi Fujita, Fumio Nagashima, Wataru Yamamoto et al. · Biological and Pharmaceutical Bulletin · 2008 · 38 citations · Full text

Medicine, Oncology, Pharmacology +17